Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells	Antibodies

|<
<<
Previous
Page 1006 of 3330
Next
>>
>
25126 to 25150 of 83232 records
per page:

Cell	Clinical Subtype	Transcriptional Subtype	Small Molecule	Perturbagen Target	Perturbagen Class	Perturbagen Concentration	Perturbagen Conc Unit	Biological Replicate ID	Relative Cell Count	Normalized Growth Rate Inhibition Value	Nominal Division Rate
MB 157	Unknown	Unknown	Everolimus	MTOR	MTOR	2.67	uM	12580.164	0.4915	0.4241	2.0914
MB 157	Unknown	Unknown	Everolimus	MTOR	MTOR	13.3	uM	12580.164	0.4823	0.4112	2.0914
MB 157	Unknown	Unknown	Everolimus	MTOR	MTOR	66.7	uM	12580.164	0.2356	0.0020	2.0914
MCF 10A	NM	Basal B	Everolimus	MTOR	MTOR	0.000171	uM	11056.156	1.0351	1.0269	2.5844
MCF 10A	NM	Basal B	Everolimus	MTOR	MTOR	0.000853	uM	11056.156	0.9679	0.9749	2.5844
MCF 10A	NM	Basal B	Everolimus	MTOR	MTOR	0.00427	uM	11056.156	0.8973	0.9179	2.5844
MCF 10A	NM	Basal B	Everolimus	MTOR	MTOR	0.0213	uM	11056.156	0.7863	0.8224	2.5844
MCF 10A	NM	Basal B	Everolimus	MTOR	MTOR	0.107	uM	11056.156	0.6753	0.7182	2.5844
MCF 10A	NM	Basal B	Everolimus	MTOR	MTOR	0.533	uM	11056.156	0.5849	0.6252	2.5844
MCF 10A	NM	Basal B	Everolimus	MTOR	MTOR	2.67	uM	11056.156	0.5721	0.6113	2.5844
MCF 10A	NM	Basal B	Everolimus	MTOR	MTOR	13.3	uM	11056.156	0.4411	0.4571	2.5844
MCF 10A	NM	Basal B	Everolimus	MTOR	MTOR	66.7	uM	11056.156	0.0068	-0.7096	2.5844
MCF 10F	NM	-	Everolimus	MTOR	MTOR	0.000171	uM	12254.164	0.9696	0.9581	1.4589
MCF 10F	NM	-	Everolimus	MTOR	MTOR	0.000853	uM	12254.164	0.9877	0.9830	1.4589
MCF 10F	NM	-	Everolimus	MTOR	MTOR	0.00427	uM	12254.164	1.0681	1.0924	1.4589
MCF 10F	NM	-	Everolimus	MTOR	MTOR	0.0213	uM	12254.164	0.8303	0.7607	1.4589
MCF 10F	NM	-	Everolimus	MTOR	MTOR	0.107	uM	12254.164	0.6702	0.5203	1.4589
MCF 10F	NM	-	Everolimus	MTOR	MTOR	0.533	uM	12254.164	0.7013	0.5683	1.4589
MCF 10F	NM	-	Everolimus	MTOR	MTOR	2.67	uM	12254.164	0.6641	0.5108	1.4589
MCF 10F	NM	-	Everolimus	MTOR	MTOR	13.3	uM	12254.164	0.6056	0.4182	1.4589
MCF 10F	NM	-	Everolimus	MTOR	MTOR	66.7	uM	12254.164	0.3259	-0.0725	1.4589
MCF12A	NM	Basal B	Everolimus	MTOR	MTOR	0.000171	uM	12365.164	0.9629	0.9639	2.0756
MCF12A	NM	Basal B	Everolimus	MTOR	MTOR	0.000853	uM	12365.164	0.9167	0.9179	2.0756
MCF12A	NM	Basal B	Everolimus	MTOR	MTOR	0.00427	uM	12365.164	0.9568	0.9579	2.0756
MCF12A	NM	Basal B	Everolimus	MTOR	MTOR	0.0213	uM	12365.164	0.9428	0.9441	2.0756

|<
<<
Previous
Page 1006 of 3330
Next
>>
>
25126 to 25150 of 83232 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)